Finance

Lists
Why is SPRY down 7.24%?
Dive Deeper
SPRY:NASDAQ
ARS Pharmaceuticals Inc
$4.23
-7.24%
(-0.33) 1D
$4.33
+2.36% (+0.100)
After hours
Closed: Oct 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPRY...
Open
$4.53
High
$4.56
Low
$4.20
Mkt. cap
420.66M
Avg. vol.
1.45M
Volume
1.26M
52-wk high
$13.15
52-wk low
$3.99
EPS
-$2.17
Beta
0.85
Shares outstanding
99.45M
No. of employees
198
Open
$4.53
High
$4.56
Low
$4.20
Mkt. cap
420.66M
Avg. vol.
1.45M
Volume
1.26M
52-wk high
$13.15
52-wk low
$3.99
EPS
-$2.17
Beta
0.85
Shares outstanding
99.45M
No. of employees
198
News stories
From web sources and news partners
About ARS Pharmaceuticals Inc
CEO-
Employees198
Founded2015
Headquarters-
SectorBiotechnology
Websitears-pharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to SPRY in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for SPRY in the last 3 months.
Highest
Current $4.23
$30.00 (+609.22%)
Average
$22.50 (+431.91%)
Lowest
$15.00 (+254.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Roanna Ruiz
Leerink Partners
Buy
Maintained
$15.00
+254.6%
09/08/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$30.00
+609.2%
08/14/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/14/2026
Carl Byrnes
Northland Securities
Buy
Maintained
$25.00
+491%
04/15/2026
Kyle Bauser
Roth MKM
Buy
Reiterated
$30.00
+609.2%
04/14/2026
Ryan Deschner
Raymond James
Buy
Maintained
-
-
01/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
32.50M
28.09M
22.68M
33.66M
Cost of goods sold
10.94M
9.60M
10.62M
17.54M
Cost of revenue
10.94M
9.60M
10.62M
17.54M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
74.75M
59.96M
72.20M
77.58M
Operating expense
74.75M
59.96M
72.20M
77.58M
Total operating expenses
85.69M
69.55M
82.83M
95.12M
Operating income
-53.19M
-41.46M
-60.14M
-61.46M
Other non operating income
2.04M
-3.49M
-
-
EBT including unusual items
-51.15M
-41.40M
-60.62M
-62.34M
EBT excluding unusual items
-51.15M
-36.88M
-60.62M
-62.34M
Income tax expense
-
-80.00K
-
-
Effective tax rate
-
0.19%
-
-
Other operating expenses
-
-
-
-
Net income
-51.15M
-41.32M
-60.62M
-62.34M
Net profit margin
-157.38%
-147.13%
-267.26%
-185.21%
Earnings per share
-0.52
-0.42
-0.61
-0.63
Interest and investment income
-
10.67M
1.97M
1.60M
Interest expense
-
-2.60M
-2.44M
-2.48M
Net interest expenses
-
8.07M
-473.00K
-874.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-52.80M
-41.05M
-59.75M
-61.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps